Novoprotein announced that its operating revenue in the first half of 2025 was 72.0946 million yuan, a year-on-year increase of 20.85%. The net loss attributable to shareholders of the listed company was 24.2236 million yuan, compared to a net loss of 8.9058 million yuan in the same period last year. The net cash flow from operating activities was -14.0835 million yuan, compared to 23.2983 million yuan in the same period last year